A Phase III, Multicentre, Randomised, Open-label, Parallel, Active-controlled Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis
Phase of Trial: Phase III
Latest Information Update: 15 Jun 2018
At a glance
- Drugs Triptorelin (Primary)
- Indications Endometriosis
- Focus Therapeutic Use
- Sponsors Ipsen
- 08 Jun 2018 Planned End Date changed from 28 Feb 2019 to 28 Feb 2020.
- 08 Jun 2018 Planned primary completion date changed from 28 Feb 2019 to 31 Oct 2019.
- 28 Aug 2017 Status changed from not yet recruiting to recruiting.